News

No unexpected safety signals were reported in the post hoc analysis.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Eligible patients with Duchenne muscular dystrophy may receive the drug while it is under priority review by the FDA.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed the comorbidities related to narcolepsy.

The risk of relapse was higher with treatment of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorder and other first-line immunosuppressants, compared to treatment with rituximab.

The chief medical officer at SK Life Science discussed what the clinical community needs to know with cenobamate headed to the market in the second quarter of this year.

Lead author Amrou Sarraj, MD, discussed the findings of an assessment of more than 1900 stroke centers and the challenges in EVT access for stroke care.

Neurology News Network for the week ending March 21, 2020.

Neuro-oncology fellow Ashley Aaroe recounts her experience at Neurology on the Hill, advocating for important changes in neurology health care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 20, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Barry A. Singer, MD, and Nina Riggins, MD, PhD.

The assistant professor of neurology in the Stroke Division and Department of Neurology at the University of Miami Miller School of Medicine spoke to the current limitations of advanced imaging to aid in the treatment of stroke.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

Results from a study of 55 patients with temporal lobe epilepsy who underwent surgery suggest that resection may result in hippocampal atrophy and memory decline as a result of disruption of a memory network that includes the temporal lobe.

The oral selective S1P1 receptor modulator functionally inhibits S1P activity and reduces circulating lymphocytes.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.

The assistant professor of neurology in the Stroke Division and Department of Neurology at the University of Miami Miller School of Medicine discussed the thrombolysis pro-con debate at ISC 2020, and the role of perfusion imaging.